Slingshot Biosciences is revolutionizing cell-based assay controls with its proprietary cell mimic technology. Founded in 2012 in the San Francisco Bay Area, the company spent a decade perfecting its platform before launching commercially in 2022. Slingshot’s cell mimics combine the best features of cells and polymers to deliver better, cheaper, faster, and more reliable controls than traditional cell lines or donor material. With market-leading lot-to-lot consistency, full customizability, and availability of rare biomarkers, Slingshot Biosciences is on a mission to improve quality and reproducibility in cell-based therapies and diagnostics. The company has grown to over 50 employees, holds more than 20 patents, and serves over 500 adopters globally across pharmaceutical, biotech, and clinical research applications. Learn more at slingshotbio.com.

Company (Headquarters):

United States

Company Products and Services:

Clinical Research;CMO/CDMO;Contract Research Organization CRO;Clinical Trial Supply Solution

Number of Facilities:

1

Facilities Location:

North America

Regulatory Approvals for facilities:

ISO 13485